Literature DB >> 21913189

Incidence and survival of malignant bone sarcomas in England 1979-2007.

Jeremy Whelan1, Anne McTiernan, Nicola Cooper, Yuen K Wong, Matthew Francis, Sally Vernon, Sandra J Strauss.   

Abstract

Primary malignant bone sarcomas (MBS) are rare and there are few studies examining their incidence and outcome. Here, the incidence and survival of all subtypes of MBS registered in England between 1979 and 2007 were analysed from patient registry data held by the National Cancer Intelligence Network (NCIN). Over 11,002 new cases of MBS were registered, an average of 379 per year. There was no change in incidence demonstrated over the study period (p = 0.08). Although a peak incidence is observed in adolescence, approximately half of MBS are diagnosed in patients over 50 years. An improvement in outcome of MBS was observed between those patients registered from 1979 to 1983 and 1983 to 1987 (p < 0.0001), but there has been no improvement since. In the most recent period studied (patients diagnosed 1998-2002) 5-year survival was 55% in Ewing sarcoma, 70% in chondrosarcoma, 56% in chordoma and 43% in osteosarcoma. Patients diagnosed with osteosarcoma over the age of 40 years or with a non-extremity tumour have a significantly inferior outcome; 22% 5-year survival >40 years compared with 53% <40 years (p < 0.0001) and 16% non-extremity tumour compared to 48% extremity tumour (p < 0.0001). This population-based study has allowed us to confidently define the English incidence and survival rates of both the commoner bone tumours such as osteosarcoma, and rarer entities such as chordoma as well as groups with inferior outcome. The lack of significant improvement over recent decades for these diseases is cause for concern and further research.
Copyright © 2011 UICC.

Entities:  

Mesh:

Year:  2011        PMID: 21913189     DOI: 10.1002/ijc.26426

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  75 in total

1.  One-year mortality in patients with bone and soft tissue sarcomas as an indicator of delay in presentation.

Authors:  R Nandra; N Hwang; G S Matharu; K Reddy; R Grimer
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

2.  The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells.

Authors:  Jun Gao; Chao Zhang; Feng Gao; Hongzhu Li
Journal:  Mol Cell Biochem       Date:  2017-02-08       Impact factor: 3.396

3.  OUTCOME OF CLIVAL CHORDOMAS AFTER SKULL BASE SURGERIES WITH MEAN FOLLOW-UP OF 10 YEARS.

Authors:  Takamitsu Tamura; Taku Sato; Yugo Kishida; Masahiro Ichikawa; Keiko Oda; Eiji Ito; Tadashi Watanabe; Jun Sakuma; Kiyoshi Saito
Journal:  Fukushima J Med Sci       Date:  2015-09-11

4.  [Imaging diagnostics of bone sarcomas].

Authors:  J A Krämer; R Gübitz; L Beck; W Heindel; V Vieth
Journal:  Unfallchirurg       Date:  2014-06       Impact factor: 1.000

5.  Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Authors:  Zhenjiang Zhao; Guoguo Jin; Ke Yao; Kangdong Liu; Fangfang Liu; Hanyong Chen; Keke Wang; Dhilli Rao Gorja; Kanamata Reddy; Ann M Bode; Zhiping Guo; Zigang Dong
Journal:  Mol Carcinog       Date:  2019-03-01       Impact factor: 4.784

6.  An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.

Authors:  Andrew C Nelson; Nischalan Pillay; Stephen Henderson; Nadège Presneau; Roberto Tirabosco; Dina Halai; Fitim Berisha; Paul Flicek; Derek L Stemple; Claudio D Stern; Fiona C Wardle; Adrienne M Flanagan
Journal:  J Pathol       Date:  2012-09-26       Impact factor: 7.996

7.  Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup.

Authors:  Jakob K Anninga; Piero Picci; Marta Fiocco; Herman M J A Kroon; Daniel Vanel; Marco Alberghini; Hans Gelderblom; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-05       Impact factor: 4.064

8.  WRN Cys1367Arg polymorphism is not associated with skull base chordoma.

Authors:  Ke Wang; Liang Wang; Jie Feng; Shuyu Hao; Kaibing Tian; Zhen Wu; Liwei Zhang; Guijun Jia; Hong Wan; Junting Zhang
Journal:  Biomed Rep       Date:  2014-05-15

9.  Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples.

Authors:  Xuan Dung Ho; Phuong Phung; Van Q Le; Van H Nguyen; Ene Reimann; Ele Prans; Gea Kõks; Katre Maasalu; Nghi Tn Le; Le H Trinh; Hoang G Nguyen; Aare Märtson; Sulev Kõks
Journal:  Exp Biol Med (Maywood)       Date:  2017-10-19

10.  Effect of Period 2 on the proliferation, apoptosis and migration of osteosarcoma cells, and the corresponding mechanisms.

Authors:  Tao Qin; Xiao-Ting Lu; Yong-Gang Li; Yan Liu; Wenjiang Yan; Na Li; Yuan-Yuan Sun
Journal:  Oncol Lett       Date:  2018-06-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.